graphic
News > Deals
Celera acquires Axys
June 13, 2001: 8:16 p.m. ET

Celera Genomics acquires Axys for $174M to expand into drug discovery
graphic
graphic graphic
graphic
NEW YORK (CNNfn) - Celera Genomics has agreed to acquire Axys Pharmaceuticals Inc. for about $174 million in stock as part of its plan to expand into drug discovery.

The companies said Wednesday Axys shareholders will receive 0.1016 share of Celera stock if Celera's 10-day average share price is between $45.77 and $48.23 up until two days prior to the deal closing. If the price falls below the collar range Axys shareholders will get $4.65 per share, and $4.90 if it is above.

Celera (CRA: Research, Estimates) shares closed up 60 cents to $42.35 on Wednesday, while Axys (AXPH: Research, Estimates) rose 91 cents to $4.36.

"Building on its genomic and proteomic platform, Celera is now focused on the identification and evaluation of therapeutic targets that could form the basis of potential new treatments or cures for human disease," said J. Craig Venter, Ph.D., Celera president and chief scientific officer.

graphic  
Venter will remain as top exec after the merger.

"Axys is a very nice addition to Celera's drug discovery business," said James Reddoch, an analyst at Banc of America Securities. "It gives them a jump start in coming up with small molecule compounds for the targets they will be generating."

In a conference call with investors, Venter said the company needs to build or acquire expertise in target validation -- identifying one gene out of several genes associated with a disease that, if turned off, can cure the disease.

"By getting their owned skilled team, Celera can begin to tie together their massive data base with a research base and begin developing compounds on their own," said Daniel Morgan, portfolio manager at Noble Financial Group in Boca Raton, Fla. "That's all to the good and will help diversify their revenue base." graphic


from staff and wire reports

  RELATED STORIES

In focus: Celera, biotechs - Feb. 12, 2001

  RELATED SITES

Celera

Axys


Note: Pages will open in a new browser window
External sites are not endorsed by CNNmoney




graphic

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.